SCHEMBL2979470

SCHEMBL2979470

Oc1cccc(/C=C/c2cc(O)c(O)c(O)c2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 3/20 0.73
ABL1 P00519 1/20 0.59
BCR P11274 1/20 0.59
CCNB2 O95067 1/20 0.55
CDK1 P06493 1/20 0.55
CDK4 P11802 1/20 0.55
CCNB1 P14635 1/20 0.55
CCND1 P24385 1/20 0.55
CCNB3 Q8WWL7 1/20 0.55
ALOX12 P18054 2/20 0.53
TTR P02766 2/20 0.53
MEN1 O00255 2/20 0.53
NPC1 O15118 2/20 0.53
KMT2A Q03164 2/20 0.53
RGS12 O14924 1/20 0.53
TP53 P04637 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
PKM P14618 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2979473 1.00 LCK (0.73) LCKABL1BCRCCNB2CDK1
SCHEMBL13338339 0.87 LCK (0.86) LCKABL1BCRCCNB2CDK1
SCHEMBL2512334 0.87 LCK (0.86) LCKABL1BCRCCNB2CDK1
SCHEMBL2512336 0.87 LCK (0.86) LCKABL1BCRCCNB2CDK1
SCHEMBL23754267 0.85 LCK (1.00) LCKABL1BCRCCNB2CDK1
SCHEMBL4742460 0.85 LCK (1.00) LCKABL1BCRCCNB2CDK1
SCHEMBL30194225 0.85 LCK (1.00) LCKABL1BCRCCNB2CDK1
SCHEMBL3392045 0.85 LCK (0.91) LCKABL1BCRCCNB2CDK1
SCHEMBL23754269 0.85 LCK (1.00) LCKABL1BCRCCNB2CDK1
SCHEMBL4742462 0.85 LCK (1.00) LCKABL1BCRCCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1075256-B1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INST NAT SANTE RECH MED (FR) 2003-07-30 EP claimed
EP-1075256-A1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-02-14 EP claimed
WO-1999056737-A1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1999-11-11 WO claimed
US-20250179435-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-05 US disclosed
EP-4049665-B1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION CHILDRENS MEDICAL CT CORP (US) 2025-03-12 EP disclosed
EP-3313420-B1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION, ENRICHMENT, AND MAINTENANCE CHILDRENS MEDICAL CT CORP (US) 2024-03-13 EP disclosed
US-11891625-B2 Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance CHILDREN'S MEDICAL CENTER CORPORATION 2024-02-06 US disclosed
EP-4049665-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION Children's Medical Center Corporation (US) 2022-08-31 EP disclosed
EP-3429603-B1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION CHILDRENS MEDICAL CENTER (US) 2021-12-29 EP disclosed
US-20200248143-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION, ENRICHMENT, AND MAINTENANCE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-08-06 US disclosed
US-10669528-B2 Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance CHILDREN'S MEDICAL CENTER CORPORATION (US) 2020-06-02 US disclosed
US-20090208432-A1 AH Receptor Antagonists SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
US-20090028804-A1 AhR mediators SYMRISE GMBH & CO. KG (DE) 2009-01-29 US disclosed
EP-1954831-A2 AHR MEDIATOR Symrise GmbH & Co. KG (DE) 2008-08-13 EP disclosed
US-20070191627-A1 Stilbene derivatives and their use in medicaments SZEKERES THOMAS 2007-08-16 US disclosed
WO-2007060256-A2 AHR MEDIATOR SYMRISE GMBH & CO. KG (DE) 2007-05-31 WO disclosed
EP-1075256-B1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INST NAT SANTE RECH MED (FR) 2003-07-30 EP disclosed
EP-1075256-A1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2001-02-14 EP disclosed
WO-1999056737-A1 ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1999-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208432-A1 AH Receptor Antagonists AHR, ARNT, HCAR1 LCK 3843/4885ABL1 1554/4885BCR 971/4885
US-20200248143-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION, ENRICHMENT, AND MAINTENANCE HDAC1, EHMT1, MCL1 LCK 561/4885ABL1 576/4885BCR 538/4885
US-20070191627-A1 Stilbene derivatives and their use in medicaments PTGS2, PTGS1, PTGER2 LCK 3040/4885ABL1 772/4885BCR 4323/4885
US-20090028804-A1 AhR mediators AHR, ARNT, HCAR1 LCK 3894/4885ABL1 1711/4885BCR 1650/4885
US-10669528-B2 Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance HDAC1, EHMT1, MCL1 LCK 561/4885ABL1 576/4885BCR 538/4885
US-20090208433-A1 aryl hydrocarbon receptor (Ah receptor; AhR) antagonists such as 2-benzylidene-5,6-dimethoxy-3H-inden-1-one, used for preventing a translocation of an AhR into a cell nucleus, ultraviolet radiation-induced gene expression or skin damage; cosmetics; sunscreen agents; aldol condensation AHR, ARNT, AIPL1 LCK 4583/4885ABL1 4259/4885BCR 993/4885
US-20250179435-A1 METHODS AND COMPOSITIONS RELATING TO HEMATOPOIETIC STEM CELL EXPANSION MCL1, HCLS1, KIT LCK 1961/4885ABL1 43/4885BCR 8/4885
US-11891625-B2 Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance HDAC1, EHMT1, MCL1 LCK 561/4885ABL1 576/4885BCR 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.